175 related articles for article (PubMed ID: 25856425)
1. Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer.
Yuan JP; Wang LW; Qu AP; Chen JM; Xiang QM; Chen C; Sun SR; Pang DW; Liu J; Li Y
PLoS One; 2015; 10(4):e0122734. PubMed ID: 25856425
[TBL] [Abstract][Full Text] [Related]
2. Quantum dots-based double imaging combined with organic dye imaging to establish an automatic computerized method for cancer Ki67 measurement.
Wang LW; Qu AP; Liu WL; Chen JM; Yuan JP; Wu H; Li Y; Liu J
Sci Rep; 2016 Feb; 6():20564. PubMed ID: 26839163
[TBL] [Abstract][Full Text] [Related]
3. Quantum dot-based multispectral fluorescent imaging to quantitatively study co-expressions of Ki67 and HER2 in breast cancer.
Xiang QM; Wang LW; Yuan JP; Chen JM; Yang F; Li Y
Exp Mol Pathol; 2015 Aug; 99(1):133-8. PubMed ID: 26102249
[TBL] [Abstract][Full Text] [Related]
4. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
5. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
[TBL] [Abstract][Full Text] [Related]
6. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
7. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.
Muftah AA; Aleskandarany MA; Al-Kaabi MM; Sonbul SN; Diez-Rodriguez M; Nolan CC; Caldas C; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2017 Jul; 164(2):341-348. PubMed ID: 28478613
[TBL] [Abstract][Full Text] [Related]
8. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
10. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
12. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.
Serna G; Simonetti S; Fasani R; Pagliuca F; Guardia X; Gallego P; Jimenez J; Peg V; Saura C; Eppenberger-Castori S; Ramon Y Cajal S; Terracciano L; Nuciforo P
Breast; 2020 Oct; 53():102-110. PubMed ID: 32707454
[TBL] [Abstract][Full Text] [Related]
13. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer.
Stålhammar G; Robertson S; Wedlund L; Lippert M; Rantalainen M; Bergh J; Hartman J
Histopathology; 2018 May; 72(6):974-989. PubMed ID: 29220095
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens.
Yamamoto S; Ibusuki M; Yamamoto Y; Fu P; Fujiwara S; Murakami K; Iwase H
Breast Cancer; 2013 Jul; 20(3):262-70. PubMed ID: 22362219
[TBL] [Abstract][Full Text] [Related]
15. Computerized Assessment of the Tumor-stromal Ratio and Proposal of a Novel Nomogram for Predicting Survival in Invasive Breast Cancer.
Qian X; Xiao F; Chen YY; Yuan JP; Liu XH; Wang LW; Xiong B
J Cancer; 2021; 12(12):3427-3438. PubMed ID: 33995621
[No Abstract] [Full Text] [Related]
16. The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients.
Golmohammadi R; Pejhan A
J Pak Med Assoc; 2012 Sep; 62(9):871-5. PubMed ID: 23139965
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers.
Deluche E; Venat-Bouvet L; Leobon S; Fermeaux V; Mollard J; Saidi N; Jammet I; Aubard Y; Tubiana-Mathieu N
BMC Cancer; 2017 Sep; 17(1):662. PubMed ID: 28954632
[TBL] [Abstract][Full Text] [Related]
18. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.
Stathopoulou A; Vlachonikolis I; Mavroudis D; Perraki M; Kouroussis Ch; Apostolaki S; Malamos N; Kakolyris S; Kotsakis A; Xenidis N; Reppa D; Georgoulias V
J Clin Oncol; 2002 Aug; 20(16):3404-12. PubMed ID: 12177100
[TBL] [Abstract][Full Text] [Related]
19. Proliferation assessment in breast carcinomas using digital image analysis based on virtual Ki67/cytokeratin double staining.
Røge R; Riber-Hansen R; Nielsen S; Vyberg M
Breast Cancer Res Treat; 2016 Jul; 158(1):11-19. PubMed ID: 27283833
[TBL] [Abstract][Full Text] [Related]
20. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis.
Gallardo A; Garcia-Valdecasas B; Murata P; Teran R; Lopez L; Barnadas A; Lerma E
Breast Cancer Res Treat; 2018 Jan; 167(1):31-37. PubMed ID: 28865009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]